Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT01187563
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01161082
- Locations
- 🇺🇸
Site 1, Cincinnati, Ohio, United States
🇺🇸Site 2, Knoxville, Tennessee, United States
Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01074372
Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01055899
Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT01053702
Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01026597
A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01026519
- Locations
- 🇷🇺
Institute of Rheumatology under the Russian Academy of Medical Sciences, Moscow, Russian Federation
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01015027
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01011959
Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
- Conditions
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT01001715
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840017, Sacramento, California, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840026, New York, New York, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840013, Boynton Beach, Florida, United States